The latest report from the IMARC group, titled “Drug Discovery Informatics Market: Global Industry Growth, Share, Size, Trends, Opportunities and Forecasts During the Period 2022-2027”, offers a comprehensive analysis of the industry, which includes information on the drug discovery informatics market share.

The global drug discovery informatics market reached a value of US$2.7 billion in 2021. Looking ahead, IMARC Group expects the market to reach US$5.1 billion by 2027, showing a CAGR of 11. 62% over the period 2022-2027. Drug Discovery Informatics (DDI) refers to sophisticated bioinformatics algorithmic solutions that evaluate large volumes of biomechanical data regarding gene expression, drugs, and diseases. They involve a set of software and hardware tools, which help to protect databases, discover drugs for their formulation, anchor, interpret, visualize and prepare data. Apart from this, drug discovery informatics helps in generating development related information of several drugs after they are tested in clinical laboratories and in customizing systems for different aspects of data. Therefore, they are widely used in healthcare institutions, pharmaceutical companies, biotechnology organizations and contract research organizations (CROs) to make clinical decisions, manage trials and perform pharmacovigilance tasks.

We regularly monitor the direct effect of COVID-19[feminine] in the market, as well as the indirect influence of associated industries. These observations will be incorporated into the report.

Request a free sample PDF of the report: https://www.imarcgroup.com/drug-discovery-informatics-market/requestsample

Market trends:

The drug discovery informatics market is primarily driven by the increasing prevalence of various chronic disorders and the growing need for effective drug fractions at affordable prices to treat rare diseases. In this light, the sudden outbreak of coronavirus disease (COVID-19) infection has prompted the governments of several countries to invest in the pharmaceutical industry to perform drug discovery for the manufacture of new vaccines. This, in turn, has complemented the widespread adoption of drug discovery informatics to perform virtual screening of molecules, which acts as another growth-inducing factor.

Additionally, the introduction of in silico modeling tools and a physiologically based pharmacokinetic (PBK) simulator that helps support pediatric dose selection for small molecule drugs and predict pharmacokinetic outcomes is contributing to growth. of the market. Additionally, the widespread deployment of drug discovery informatics in the healthcare industry to manage biological information from multiple sources and analyze new drug entities is propelling the market growth. Other factors, such as strategic collaborations among major players and continuous investments in research and development (R&D) activities to identify various applications of drug discovery informatics and improve its efficiency, create positive prospects for the market.

Drug Discovery Informatics Competitive analysis and market segmentation 2022-2027:

Competitive landscape with key players:

The competitive landscape of the Drug Discovery Informatics market has been studied in the report along with the detailed profiles of key players operating in the market.

Some of these key players include:

• Accenture Plc
• Certara
• Charles River Laboratories Inc.
• Collaborative Drug Discovery Inc.
• Eurofins DiscoverX Products
• infosys ltd.
• International Commercial Machinery Society
• Jubilant Biosys Limited
• Oracle Corporation
• Perkin Elmer Inc.
• Selvita
• Thermo Fisher Scientific Inc.

Key Market Segmentation:

The report has segmented the global drug discovery informatics market on the basis of workflow, function, mode, end-user, and region.

Breakdown by Workflow:

• drug discovery
• Drug development

Breakdown by function:

• Sequence analysis platforms
• Molecular modeling
• Molecular docking
• Clinical Trial Data Management
• Others

Breakdown by mode:

Breakdown by end user:

• Pharmaceutical companies
• Biotechnology companies
• Contract Research Organization (CRO)
• Others

Breakdown by region:

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

Ask the analyst to customize and explore the full report with table of contents and list of figures: https://www.imarcgroup.com/request?type=report&id=3515&flag=C

Main highlights of the report:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Market trends
• Market drivers and success factors
• Impact of COVID-19
• Value chain analysis
• Complete mapping of the competitive landscape

If you need specific information that is not currently covered in the report, we will provide it to you as part of the customization.

About Us

The IMARC Group is a leading market research firm providing management strategies and market research worldwide. We partner with clients across all industries and geographies to identify their most important opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include major business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and new processing methods are at the top of the list. company expertise.

Our offerings include comprehensive market information in the form of research reports, production cost reports, feasibility studies and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our client base, ranging from small and medium-sized businesses to Fortune 1000 companies.

Contact us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, United States
Website: https://www.imarcgroup.com/
E-mail: [email protected]
Americas: +1-631-791-1145 | Europe and Africa: +44-753-713-2163 | Asia: +91-120-433-0800